Institut Pasteur De Lille

Institut National De La Sante Et De La Recherche Medicale

Institut Pasteur

Transgene S.a.

Andre Capron

Jean-Marie Grzych

Jean-Marc Balloul

Raymond Pierce

Camille Locht

Marie-Paule Kieny

Gerard Loison

Jean-Pierre Lecocq

Andre Tartar

Claude Auriault

Franco Menozzi

Gilles Riveau

Paul Sondermeyer

Veronique Pancre

Colette Dissous

Genevieve Spik

Genevieve Renauld

Jean Montreuil

Francoise Jacob-Dubuisson

Pierrette Maes

Corinne Mercier

Marie-France Cesbron

Michel Joseph

A recombinant DNA containing a sequence (1) coding for a polypeptide heterologous to a filamentous haemagglutinin of(Fha) fused within the reading frame to a sequence (2) located upstream from the first sequence. Sequence (2) codes for at least part of the Fha precursor, which part comprises at least the N-terminal region of a truncated mature Fha protein, which contains the interaction site of Fha and heparin and the secretion domain. This Fha protein is under the control of a promoter recognized by the cell polymerases ofand is inserted into acell culture, is expressed in the culture and excreted into the cell culture medium. The invention uses both the abilities ofand particularlyto secrete or surface expose the heterologous polypeptide fused to the Fha portion corresponding to sequence (2), which does not appear to produce extracellular proteases, and the ease with which filamentous haemagglutinins can be isolated from otherproteins.

RECOMBINANT PROTEINS OF FILAMENTOUS HAEMAGGLUTININ OF BORDETELLA, PARTICULARLY BORDETELLA PERTUSSIS, METHOD FOR PRODUCING SAME, AND USES THEREOF FOR PRODUCING FOREIGN PROTEINS OF VACCINATING ACTIVE PRINCIPLES

Cloning of gene encoding the GP28.5 protein of toxoplasma gondii;

An antigenic composition against S. mansoni comprising an 8 kD peptidic fragment associated with a suitable vehicle, the 8 kD peptidic fragment being obtained by controlled proteolysis using V8 protease of a 28 kD protein obtained from S. mansoni is described.

Antigenic composition obtained by V8 proteolysis of a protein from S.

The present invention relates to the development of a vaccine against schistosomiasis. It relates to a protein which includes the epitopes of the p28 protein, a poxvirus containing a gene coding for the said protein, a cell incorporating a vector for the expression of the said protein, a method for preparing the said protein, a DNA sequence coding for the p28 protein, a pharmaceutical composition, antibodies raised against the said protein and their application by way of diagnostic agents for schistosomiasis. The present invention also relates to the application of the said protein by way of an agent possessing glutathione S-transferase activity.

Protein recognized by antibodies raised against native P28 of

A hybridoma is provided which provides a monoclonal antibody of isotope IgG2a, which recognizes a strip corresponding to a peptidic fragment of 8kD, isolated by controlled proteolysis of the 28kD polypeptide of S. mansoni.

Monoclonal antibodies against the 28KD protein of S. mansoni

Novel lymphokine for suppressing platelet activation

The present invention relates to an immunogenic fraction active against bilharzioses. This glycoprotein extracted from hemocyanin of a mollusc, is characterized in that its glucidic fraction represents 5 to 25% of the glycoprotein molecule and in that the molar composition of said glucidic fraction (calculated on the basis of 3 mannose residues) is substantially the following:

Immunogenic fraction active against bilharzioses, its preparation, and

Growing community of inventors

Phalempin, France

Andre Capron